Pharmafile Logo

Merck & Co Inc

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Merck & Co Inc in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Merck & Co Inc.

Recent articles on PMLiVE featuring Merck & Co Inc

- PMLiVE
Sandoz appoints Armin Metzger as President of new global unit

Metzger was most recently Executive VP, Chief Technical Operations Officer at Ferring Pharmaceuticals

- PMLiVE
AbbVie reaches agreement for affordable prescription drugs with US government

The pharma company has also pledged a $100bn investment in US infrastructure over the next decade

- PMLiVE
Merck announces agreement with US government to reduce prices of prescription medication

The pharma company will invest more than $70bn in the US to boost production and innovation

- PMLiVE
David Weinreich appointed as Merck’s head of R&D and CMO for healthcare

Weinreich brings clinical development and venture capital experience to the role

- PMLiVE
David Weinreich appointed as Merck’s Global Head of R&D and CMO, Healthcare

Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site

- PMLiVE
MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

- PMLiVE
Merck to expand respiratory disease portfolio with $10bn Verona acquisition

The deal includes a drug approved in the US for chronic obstructive pulmonary disease

- PMLiVE
Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer

More than 72,680 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE
Merck’s RSV monoclonal antibody Enflonsia approved by FDA to protect infants

Enflonsia is now the first RSV preventive for infants that can be given at the same dose regardless of weight

- PMLiVE
Merck shares promising phase 3 results for Keytruda in ovarian cancer

Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year

- PMLiVE
MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive

Illnesses caused by Streptococcus pneumoniae are currently considered a major public health problem by WHO

- PMLiVE
Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links